Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 548 entries
Sorted by: Best Match Show Resources per page
Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology.

Annual review of pharmacology and toxicology

Steinhorn B, Eroglu E, Michel T.
PMID: 34530645
Annu Rev Pharmacol Toxicol. 2022 Jan 06;62:551-571. doi: 10.1146/annurev-pharmtox-012221-082339. Epub 2021 Sep 16.

Chemogenetics refers to experimental systems that dynamically regulate the activity of a recombinant protein by providing or withholding the protein's specific biochemical stimulus. Chemogenetic tools permit precise dynamic control of specific signaling molecules to delineate the roles of those...

Cite
Steinhorn B, Eroglu E, Michel T. Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology. Annu Rev Pharmacol Toxicol. 2021;62:551-571doi: 10.1146/annurev-pharmtox-012221-082339.
Steinhorn, B., Eroglu, E., & Michel, T. (2022). Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology. Annual review of pharmacology and toxicology, 62551-571. https://doi.org/10.1146/annurev-pharmtox-012221-082339
Steinhorn, Benjamin, et al. "Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology." Annual review of pharmacology and toxicology vol. 62 (2022): 551-571. doi: https://doi.org/10.1146/annurev-pharmtox-012221-082339
Steinhorn B, Eroglu E, Michel T. Chemogenetic Approaches to Probe Redox Pathways: Implications for Cardiovascular Pharmacology and Toxicology. Annu Rev Pharmacol Toxicol. 2022 Jan 06;62:551-571. doi: 10.1146/annurev-pharmtox-012221-082339. Epub 2021 Sep 16. PMID: 34530645.
Copy Download .nbib Format: NLM
Corrigendum to "Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models" [Journal of Pharmacological and Toxicological Methods 100 (2019) 106621].

Journal of pharmacological and toxicological methods

Świętaszczyk C, Jødal L.
PMID: 31733595
J Pharmacol Toxicol Methods. 2020 Jan - Feb;101:106648. doi: 10.1016/j.vascn.2019.106648. Epub 2019 Nov 13.

No abstract available.

Cite
Świętaszczyk C, Jødal L. Corrigendum to "Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models" [Journal of Pharmacological and Toxicological Methods 100 (2019) 106621]. J Pharmacol Toxicol Methods. 2019;101:106648doi: 10.1016/j.vascn.2019.106648.
Świętaszczyk, C., & Jødal, L. (2020). Corrigendum to "Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models" [Journal of Pharmacological and Toxicological Methods 100 (2019) 106621]. Journal of pharmacological and toxicological methods, 101106648. https://doi.org/10.1016/j.vascn.2019.106648
Świętaszczyk, Cyprian, and Jødal, Lars. "Corrigendum to "Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models" [Journal of Pharmacological and Toxicological Methods 100 (2019) 106621]." Journal of pharmacological and toxicological methods vol. 101 (2020): 106648. doi: https://doi.org/10.1016/j.vascn.2019.106648
Świętaszczyk C, Jødal L. Corrigendum to "Derivation and presentation of formulas for drug concentrations in two-, three- and four-compartment pharmacokinetic models" [Journal of Pharmacological and Toxicological Methods 100 (2019) 106621]. J Pharmacol Toxicol Methods. 2020 Jan - Feb;101:106648. doi: 10.1016/j.vascn.2019.106648. Epub 2019 Nov 13. PMID: 31733595.
Copy Download .nbib Format: NLM
The use of cerium oxide nanoparticles in liver disorders: A double-sided coin?.

Basic & clinical pharmacology & toxicology

Attia N, Rostom DM, Mashal M.
PMID: 34902883
Basic Clin Pharmacol Toxicol. 2021 Dec 13; doi: 10.1111/bcpt.13700. Epub 2021 Dec 13.

Being recognized as the first antioxidant nanoparticles (NPs) proposed for medicine, cerium oxide NPs (CeO

Cite
Attia N, Rostom DM, Mashal M. The use of cerium oxide nanoparticles in liver disorders: A double-sided coin?. Basic Clin Pharmacol Toxicol. 2021;doi: 10.1111/bcpt.13700.
Attia, N., Rostom, D. M., & Mashal, M. (2021). The use of cerium oxide nanoparticles in liver disorders: A double-sided coin?. Basic & clinical pharmacology & toxicology, . https://doi.org/10.1111/bcpt.13700
Attia, Noha, et al. "The use of cerium oxide nanoparticles in liver disorders: A double-sided coin?." Basic & clinical pharmacology & toxicology vol. (2021). doi: https://doi.org/10.1111/bcpt.13700
Attia N, Rostom DM, Mashal M. The use of cerium oxide nanoparticles in liver disorders: A double-sided coin?. Basic Clin Pharmacol Toxicol. 2021 Dec 13; doi: 10.1111/bcpt.13700. Epub 2021 Dec 13. PMID: 34902883.
Copy Download .nbib Format: NLM
A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability.

Journal of pharmacological and toxicological methods

Blanchette AD, Burnett SD, Rusyn I, Chiu WA.
PMID: 34999233
J Pharmacol Toxicol Methods. 2022 Jan 06;107154. doi: 10.1016/j.vascn.2022.107154. Epub 2022 Jan 06.

Population-wide in vitro studies for characterization of cardiotoxicity hazard, risk, and population variability show that human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are a powerful and high-throughput testing platform for drugs and environmental chemicals alike. However, studies in multiple...

Cite
Blanchette AD, Burnett SD, Rusyn I, et al. A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability. J Pharmacol Toxicol Methods. 2022;107154doi: 10.1016/j.vascn.2022.107154.
Blanchette, A. D., Burnett, S. D., Rusyn, I., & Chiu, W. A. (2022). A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability. Journal of pharmacological and toxicological methods, 107154. https://doi.org/10.1016/j.vascn.2022.107154
Blanchette, Alexander D, et al. "A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability." Journal of pharmacological and toxicological methods vol. (2022): 107154. doi: https://doi.org/10.1016/j.vascn.2022.107154
Blanchette AD, Burnett SD, Rusyn I, Chiu WA. A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability. J Pharmacol Toxicol Methods. 2022 Jan 06;107154. doi: 10.1016/j.vascn.2022.107154. Epub 2022 Jan 06. PMID: 34999233.
Copy Download .nbib Format: NLM
ADR databases for on-site clinical use: Potentials of summary of products characteristics.

Basic & clinical pharmacology & toxicology

Eiermann B, Rodriguez D, Cohen P, Gustafsson LL.
PMID: 33523597
Basic Clin Pharmacol Toxicol. 2021 Apr;128(4):557-567. doi: 10.1111/bcpt.13564. Epub 2021 Feb 24.

Adverse drug reactions (ADRs) for all drugs in Europe are described in the legally approved Summary of Product Characteristics (SmPC). An overview of all ADRs of the patients' drug list can support healthcare staff to link patient symptoms to...

Cite
Eiermann B, Rodriguez D, Cohen P, et al. ADR databases for on-site clinical use: Potentials of summary of products characteristics. Basic Clin Pharmacol Toxicol. 2021;128(4):557-567doi: 10.1111/bcpt.13564.
Eiermann, B., Rodriguez, D., Cohen, P., & Gustafsson, L. L. (2021). ADR databases for on-site clinical use: Potentials of summary of products characteristics. Basic & clinical pharmacology & toxicology, 128(4), 557-567. https://doi.org/10.1111/bcpt.13564
Eiermann, Birgit, et al. "ADR databases for on-site clinical use: Potentials of summary of products characteristics." Basic & clinical pharmacology & toxicology vol. 128,4 (2021): 557-567. doi: https://doi.org/10.1111/bcpt.13564
Eiermann B, Rodriguez D, Cohen P, Gustafsson LL. ADR databases for on-site clinical use: Potentials of summary of products characteristics. Basic Clin Pharmacol Toxicol. 2021 Apr;128(4):557-567. doi: 10.1111/bcpt.13564. Epub 2021 Feb 24. PMID: 33523597.
Copy Download .nbib Format: NLM
Chronic bladder catheterization for precise urine collection in awake mice.

Journal of pharmacological and toxicological methods

Andreev-Andrievskiy AA, Lagereva EA, Pankova NV, Mashkin MA, Manskikh VN, Frolova OY, Fadeeva OV, Telyatnikova EV.
PMID: 34678429
J Pharmacol Toxicol Methods. 2022 Jan-Feb;113:107128. doi: 10.1016/j.vascn.2021.107128. Epub 2021 Oct 19.

Metabolic chambers are routinely used for urine collection in rodents. In mice, due to small urination volume, evaporation in the metabolic chambers (≈50%) distorts diuresis and urinalysis parameters. We have developed a new technique of bladder catheterization enabling long-term...

Cite
Andreev-Andrievskiy AA, Lagereva EA, Pankova NV, et al. Chronic bladder catheterization for precise urine collection in awake mice. J Pharmacol Toxicol Methods. 2021;113:107128doi: 10.1016/j.vascn.2021.107128.
Andreev-Andrievskiy, A. A., Lagereva, E. A., Pankova, N. V., Mashkin, M. A., Manskikh, V. N., Frolova, O. Y., Fadeeva, O. V., & Telyatnikova, E. V. (2022). Chronic bladder catheterization for precise urine collection in awake mice. Journal of pharmacological and toxicological methods, 113107128. https://doi.org/10.1016/j.vascn.2021.107128
Andreev-Andrievskiy, Alexander A, et al. "Chronic bladder catheterization for precise urine collection in awake mice." Journal of pharmacological and toxicological methods vol. 113 (2022): 107128. doi: https://doi.org/10.1016/j.vascn.2021.107128
Andreev-Andrievskiy AA, Lagereva EA, Pankova NV, Mashkin MA, Manskikh VN, Frolova OY, Fadeeva OV, Telyatnikova EV. Chronic bladder catheterization for precise urine collection in awake mice. J Pharmacol Toxicol Methods. 2022 Jan-Feb;113:107128. doi: 10.1016/j.vascn.2021.107128. Epub 2021 Oct 19. PMID: 34678429.
Copy Download .nbib Format: NLM
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins.

BMC pharmacology & toxicology

Choi JY, Choi CU, Choi BG, Park Y, Kang DO, Jang WY, Kim W, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Jeong MH, Chae SC, Seong IW, Yoon CH, Cha KS, Oh SK.
PMID: 33541430
BMC Pharmacol Toxicol. 2021 Feb 04;22(1):11. doi: 10.1186/s40360-021-00476-z.

BACKGROUND: High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on...

Cite
Choi JY, Choi CU, Choi BG, et al. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacol Toxicol. 2021;22(1):11doi: 10.1186/s40360-021-00476-z.
Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., Kim, E. J., Rha, S. W., Park, C. G., Seo, H. S., Jeong, M. H., Chae, S. C., Seong, I. W., Yoon, C. H., Cha, K. S., Oh, S. K. (2021). New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC pharmacology & toxicology, 22(1), 11. https://doi.org/10.1186/s40360-021-00476-z
Choi, Jah Yeon, et al. "New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins." BMC pharmacology & toxicology vol. 22,1 (2021): 11. doi: https://doi.org/10.1186/s40360-021-00476-z
Choi JY, Choi CU, Choi BG, Park Y, Kang DO, Jang WY, Kim W, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Jeong MH, Chae SC, Seong IW, Yoon CH, Cha KS, Oh SK. New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacol Toxicol. 2021 Feb 04;22(1):11. doi: 10.1186/s40360-021-00476-z. PMID: 33541430; PMCID: PMC7863364.
Copy Download .nbib Format: NLM
CORRIGENDUM.

Basic & clinical pharmacology & toxicology

[No authors listed]
PMID: 34405964
Basic Clin Pharmacol Toxicol. 2021 Sep;129(3):283. doi: 10.1111/bcpt.13630.

No abstract available.

Cite
CORRIGENDUM. Basic Clin Pharmacol Toxicol. 2021;129(3):283doi: 10.1111/bcpt.13630.
(2021). CORRIGENDUM. Basic & clinical pharmacology & toxicology, 129(3), 283. https://doi.org/10.1111/bcpt.13630
"CORRIGENDUM." Basic & clinical pharmacology & toxicology vol. 129,3 (2021): 283. doi: https://doi.org/10.1111/bcpt.13630
CORRIGENDUM. Basic Clin Pharmacol Toxicol. 2021 Sep;129(3):283. doi: 10.1111/bcpt.13630. PMID: 34405964.
Copy Download .nbib Format: NLM
Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.

Annual review of pharmacology and toxicology

Khan S, Hauptman R, Kelly L.
PMID: 33049161
Annu Rev Pharmacol Toxicol. 2021 Jan 06;61:159-179. doi: 10.1146/annurev-pharmtox-031620-031509. Epub 2020 Oct 13.

In the past decade of microbiome research, we have learned about numerous adverse interactions between the microbiome and medical interventions such as drugs, radiation, and surgery. What if we could alter our microbiomes to prevent these events? In this...

Cite
Khan S, Hauptman R, Kelly L. Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities. Annu Rev Pharmacol Toxicol. 2020;61:159-179doi: 10.1146/annurev-pharmtox-031620-031509.
Khan, S., Hauptman, R., & Kelly, L. (2021). Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities. Annual review of pharmacology and toxicology, 61159-179. https://doi.org/10.1146/annurev-pharmtox-031620-031509
Khan, Saad, et al. "Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities." Annual review of pharmacology and toxicology vol. 61 (2021): 159-179. doi: https://doi.org/10.1146/annurev-pharmtox-031620-031509
Khan S, Hauptman R, Kelly L. Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities. Annu Rev Pharmacol Toxicol. 2021 Jan 06;61:159-179. doi: 10.1146/annurev-pharmtox-031620-031509. Epub 2020 Oct 13. PMID: 33049161.
Copy Download .nbib Format: NLM
Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol.

Basic & clinical pharmacology & toxicology

Oliveira-Paula GH, Pereira DA, Pinheiro LC, Ferreira GC, Paula-Garcia WN, Garcia LV, Lacchini R, Luizon MR, Tanus-Santos JE.
PMID: 34825477
Basic Clin Pharmacol Toxicol. 2021 Nov 25; doi: 10.1111/bcpt.13691. Epub 2021 Nov 25.

Anaesthesia with propofol is frequently associated with hypotension, which is at least partially attributable to increased nitric oxide (NO) formation derived from the activation of protein kinase C (PKC)/endothelial NO synthase (NOS3) axis. In this cross-sectional study, we tested...

Cite
Oliveira-Paula GH, Pereira DA, Pinheiro LC, et al. Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol. Basic Clin Pharmacol Toxicol. 2021;doi: 10.1111/bcpt.13691.
Oliveira-Paula, G. H., Pereira, D. A., Pinheiro, L. C., Ferreira, G. C., Paula-Garcia, W. N., Garcia, L. V., Lacchini, R., Luizon, M. R., & Tanus-Santos, J. E. (2021). Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol. Basic & clinical pharmacology & toxicology, . https://doi.org/10.1111/bcpt.13691
Oliveira-Paula, Gustavo H, et al. "Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol." Basic & clinical pharmacology & toxicology vol. (2021). doi: https://doi.org/10.1111/bcpt.13691
Oliveira-Paula GH, Pereira DA, Pinheiro LC, Ferreira GC, Paula-Garcia WN, Garcia LV, Lacchini R, Luizon MR, Tanus-Santos JE. Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol. Basic Clin Pharmacol Toxicol. 2021 Nov 25; doi: 10.1111/bcpt.13691. Epub 2021 Nov 25. PMID: 34825477.
Copy Download .nbib Format: NLM
Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.

Basic & clinical pharmacology & toxicology

Eisenmann ED, Talebi Z, Sparreboom A, Baker SD.
PMID: 34117715
Basic Clin Pharmacol Toxicol. 2021 Jun 12; doi: 10.1111/bcpt.13623. Epub 2021 Jun 12.

Oral anticancer drugs suffer from significant variability in pharmacokinetics and pharmacodynamics partially due to limited bioavailability. The limited bioavailability of anticancer drugs is due to both pharmaceutical limitations and physiological barriers. Pharmacokinetic boosting is a strategy to enhance the...

Cite
Eisenmann ED, Talebi Z, Sparreboom A, et al. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2021;doi: 10.1111/bcpt.13623.
Eisenmann, E. D., Talebi, Z., Sparreboom, A., & Baker, S. D. (2021). Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic & clinical pharmacology & toxicology, . https://doi.org/10.1111/bcpt.13623
Eisenmann, Eric D, et al. "Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions." Basic & clinical pharmacology & toxicology vol. (2021). doi: https://doi.org/10.1111/bcpt.13623
Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2021 Jun 12; doi: 10.1111/bcpt.13623. Epub 2021 Jun 12. PMID: 34117715; PMCID: PMC8665934.
Copy Download .nbib Format: NLM
Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites.

BMC pharmacology & toxicology

Rahman MS, Yoshida N, Tsuboi H, Maeda E, Ibarra AVV, Zin T, Akimoto Y, Tanimoto T, Kimura K.
PMID: 33653417
BMC Pharmacol Toxicol. 2021 Mar 02;22(1):12. doi: 10.1186/s40360-021-00478-x.

BACKGROUND: Poor quality medicines have serious implications for public health. The aim of this study was to explore the quality of the antidiabetic pioglitazone, using samples collected in China and Myanmar, and samples purchased online.METHODS: In this cross-sectional study,...

Cite
Rahman MS, Yoshida N, Tsuboi H, et al. Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites. BMC Pharmacol Toxicol. 2021;22(1):12doi: 10.1186/s40360-021-00478-x.
Rahman, M. S., Yoshida, N., Tsuboi, H., Maeda, E., Ibarra, A. V. V., Zin, T., Akimoto, Y., Tanimoto, T., & Kimura, K. (2021). Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites. BMC pharmacology & toxicology, 22(1), 12. https://doi.org/10.1186/s40360-021-00478-x
Rahman, Mohammad Sofiqur, et al. "Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites." BMC pharmacology & toxicology vol. 22,1 (2021): 12. doi: https://doi.org/10.1186/s40360-021-00478-x
Rahman MS, Yoshida N, Tsuboi H, Maeda E, Ibarra AVV, Zin T, Akimoto Y, Tanimoto T, Kimura K. Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites. BMC Pharmacol Toxicol. 2021 Mar 02;22(1):12. doi: 10.1186/s40360-021-00478-x. PMID: 33653417; PMCID: PMC7923830.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 548 entries